BACE1
Levels of the BACE1 (a membrane-bound protease that catalyzes the initial and rate-limiting cleavage event of the amyloid precursor protein to form the β amyloid peptide) is increased in the plasma of AD patients and have a high specificity (88%) for AD, indicating BACE1 may be a potential candidate biomarker to predict AD.
Patients with AD
88 AD patients and 72 control individuals
blood draw, mild discomfort, in clinic visits
phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)
Other groups have historically looked at this biomarker, but this is the most recent experiment I found on pubmed: Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University; Institute of public health management of Wenzhou Medical University;Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University;Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University
-
“BACE1 Gets Attention as Potential Alzheimer’s Biomarker.”Alzforum. https://www.alzforum.org/news/research-news/bace1-gets-attention-potential-alzheimers-biomarker.
-
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015). Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 36(5), 297-309. https://www.ncbi.nlm.nih.gov/pubmed/25840462
- Feng, L., Liao, Y. T., He, J. C., Xie, C. L., Chen, S. Y., Fan, H. H., ... & Wang, Z. (2018). Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. BMC neurology, 18(1), 4. https://www.ncbi.nlm.nih.gov/pubmed/29316899